5 Best Biotech Stocks to Buy According to Analysts

4. Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Price Target Upside: 69.67%

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is one of the best biotech stocks on this list.

TheFly reported on June 18 that Baird increased its price target on NRIX to $33 from $26 while maintaining an Outperform rating on the shares. The firm adjusted its valuation to account for the company’s partnership with Roche and continued progress across its clinical programs.

Separately, earlier on June 11, Nurix Therapeutics, Inc. (NASDAQ:NRIX) reported updated clinical findings from its ongoing NX-5948-301 Phase 1a/b trial evaluating bexobrutideg (NX-5948), an investigational oral CNS-penetrant BTK degrader, in patients with chronic lymphocytic leukemia (CLL). The data showed continued durable responses in heavily pretreated patients along with encouraging activity in earlier treatment settings. Across 142 Phase 1a/b CLL patients, bexobrutideg demonstrated a favorable safety profile, with no dose-limiting toxicities or treatment-related Grade 5 adverse events. In relapsed/refractory CLL patients, the therapy achieved an objective response rate of 83% with a median progression-free survival of 22.1 months. Earlier-line cohorts also showed strong activity, including ORRs of 92.9% and 84.2% in evaluated groups. The results support further development of bexobrutideg, including a planned Phase 3 monotherapy program.

Nurix Therapeutics, Inc. (NASDAQ:NRIX) is a clinical-stage biopharmaceutical company developing targeted protein degradation therapies and other treatments for cancer and autoimmune diseases.